Ashland predicts ISP buy will accelerate pharma unit growth
Ashland expects integration of ISP and demand for pharma ingredients to drive “accelerated growth” in the next few years.
Ashland expects integration of ISP and demand for pharma ingredients to drive “accelerated growth” in the next few years.
Eli Lilly is consolidating its global recruitment processes in major markets through an outsourcing deal with Kenexa.
India plans to end price control of bulk drugs as the practice ‘is inherently anti-competitive’ and gives China an advantage.
Icon’s staffing and resourcing division DOCS has launched four new European offices.
Net profit at Indian API and formulation business Aanjaneya Lifecare jumped as it enacted post-IPO expansion plans to ‘dominate’ its markets.
Twelve of the top 20 Big Pharmas could soon outsource 100 per cent of their clinical trial work using one of two strategic partnering models according to a speaker at contract research industry conference in Lyon, France yesterday.